Novel, potent and selective cyclin D1/CDK4 inhibitors:: Indolo[6,7-a]pyrrolo[3,4-c]carbazoles

被引：57

作者：

Engler, TA ^{[1
]}

Furness, K

Malhotra, S

Sanchez-Martinez, C

Shih, C

Xie, W

Zhu, GX

Zhou, X

Conner, S

Faul, MM

Sullivan, KA

Kolis, SP

Brooks, HB

Patel, B

Schultz, RM

DeHahn, TB

Kirmani, K

Spencer, CD

Watkins, SA

Considine, EL

Dempsey, JA

Ogg, CA

Stamm, NB

Anderson, BD

Campbell, RM

Vasudevan, V

Lytle, ML

机构：

[1] Eli Lilly & Co, Lilly Res Lab, Indianapolis, IN 46285 USA

[2] Lilly Spain SA, Madrid 28108, Spain

[3] Eli Lilly & Co, Chem Proc Res & Dev, Indianapolis, IN 46285 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2003年 / 13卷 / 14期

关键词：

D O I：

10.1016/S0960-894X(03)00461-X

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The synthesis and CDK inhibitory properties of a series of indolo[6,7-a]pyrrolo[3,4-c]carbazoles is reported. In addition to their potent CDK activity, the compounds display antiproliferative activity against two human cancer cell lines. These inhibitors also effect strong G1 arrest in these cell lines and inhibit Rb phosphorylation at Ser780 consistent with inhibition of cyclin D1/CDK4. (C) 2003 Elsevier Science Ltd. All rights reserved.

引用

页码：2261 / 2267

页数：7

共 59 条

[31] A CELL-CYCLE REGULATOR POTENTIALLY INVOLVED IN GENESIS OF MANY TUMOR TYPES [J].

KAMB, A ;

GRUIS, NA ;

WEAVERFELDHAUS, J ;

LIU, QY ;

HARSHMAN, K ;

TAVTIGIAN, SV ;

STOCKERT, E ;

DAY, RS ;

JOHNSON, BE ;

SKOLNICK, MH .

SCIENCE, 1994, 264 (5157) :436-440

[32] Overexpression of cyclin D1 and cdk4 in tumorigenesis of sporadic hepatoblastomas [J].

Kim, H ;

Ham, EK ;

Kim, YI ;

Chi, JG ;

Lee, HS ;

Park, SH ;

Jung, YM ;

Myung, NK ;

Lee, MJ ;

Jang, JJ .

CANCER LETTERS, 1998, 131 (02) :177-183

[33] The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2 [J].

Kitagawa, M ;

Higashi, H ;

Jung, HK ;

SuzukiTakahashi, I ;

Ikeda, M ;

Tamai, K ;

Kato, J ;

Segawa, K ;

Yoshida, E ;

Nishimura, S ;

Taya, Y .

EMBO JOURNAL, 1996, 15 (24) :7060-7069

[34] Purification, characterization, and kinetic mechanism of cyclin D1•CDK4, a major target for cell cycle regulation [J].

Konstantinidis, AK ;

Radhakrishnan, R ;

Gu, F ;

Rao, RN ;

Yeh, WK .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (41) :26506-26515

[35] Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating β-catenin/TCF signalling [J].

Liu, WG ;

Dong, XY ;

Mai, M ;

Seelan, RS ;

Taniguchi, K ;

Krishnadath, KK ;

Halling, KC ;

Cunningham, JM ;

Qian, CP ;

Christensen, E ;

Roche, PC ;

Smith, DI ;

Thibodeau, SN .

NATURE GENETICS, 2000, 26 (02) :146-147

[36]

Mallory F.B., 1984, ORG REACTIONS, V30, P3

[37] Cyclin-dependent kinases inhibitors as potential anticancer, antineurodegenerative, antiviral and antiparasitic agents [J].

Meijer, L .

DRUG RESISTANCE UPDATES, 2000, 3 (02) :83-88

[38] Cyclin-dependent kinases: Engines, clocks, and microprocessors [J].

Morgan, DO .

ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, 1997, 13 :261-291

[39] Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 2. Probing the indeno ring substituent pattern [J].

Nugiel, DA ;

Vidwans, A ;

Etzkorn, AM ;

Rossi, KA ;

Benfield, PA ;

Burton, CR ;

Cox, S ;

Doleniak, D ;

Seitz, SP .

JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (24) :5224-5232

[40] Cell cycle regulation in the G1 phase: A promising target for the development of new chemotherapeutic anticancer agents [J].

Owa, T ;

Yoshino, H ;

Yoshimatsu, K ;

Nagasu, T .

CURRENT MEDICINAL CHEMISTRY, 2001, 8 (12) :1487-1503

← 1 2 3 4 5 6 →